Staley Capital Advisers Has Boosted Stake in Cvs Health (CVS); Axogen (AXGN) Holder S Squared Technology Decreased Holding as Stock Price Rose

December 8, 2017 - By Vivian Park

Staley Capital Advisers Inc increased its stake in Cvs Health Corp (CVS) by 3.54% based on its latest 2017Q2 regulatory filing with the SEC. Staley Capital Advisers Inc bought 19,340 shares as the company’s stock declined 4.23% while stock markets rallied. The institutional investor held 564,900 shares of the medical and nursing services company at the end of 2017Q2, valued at $45.45M, up from 545,560 at the end of the previous reported quarter. Staley Capital Advisers Inc who had been investing in Cvs Health Corp for a number of months, seems to be bullish on the $72.01 billion market cap company. The stock decreased 0.41% or $0.29 during the last trading session, reaching $71.09. About 12.37M shares traded or 40.65% up from the average. CVS Health Corporation (NYSE:CVS) has declined 24.40% since December 8, 2016 and is downtrending. It has underperformed by 41.10% the S&P500.

S Squared Technology Llc decreased its stake in Axogen Inc. (AXGN) by 6.61% based on its latest 2017Q2 regulatory filing with the SEC. S Squared Technology Llc sold 20,000 shares as the company’s stock rose 35.94% with the market. The hedge fund held 282,614 shares of the health care company at the end of 2017Q2, valued at $4.73M, down from 302,614 at the end of the previous reported quarter. S Squared Technology Llc who had been investing in Axogen Inc. for a number of months, seems to be less bullish one the $901.78 million market cap company. The stock increased 1.34% or $0.35 during the last trading session, reaching $26.45. About 356,425 shares traded or 24.92% up from the average. AxoGen, Inc. (NASDAQ:AXGN) has risen 181.49% since December 8, 2016 and is uptrending. It has outperformed by 164.79% the S&P500.

S Squared Technology Llc, which manages about $136.14M and $116.95M US Long portfolio, upped its stake in Radisys Corp Com (NASDAQ:RSYS) by 106,500 shares to 413,402 shares, valued at $1.55 million in 2017Q2, according to the filing.

Among 7 analysts covering AxoGen (NASDAQ:AXGN), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AxoGen had 16 analyst reports since August 11, 2015 according to SRatingsIntel. As per Thursday, November 3, the company rating was downgraded by Lake Street. Wedbush maintained the shares of AXGN in report on Friday, August 28 with “Outperform” rating. The stock has “Buy” rating by Roth Capital on Monday, September 11. The firm has “Outperform” rating by Wedbush given on Monday, November 7. As per Monday, August 21, the company rating was maintained by Cantor Fitzgerald. The rating was maintained by Wedbush on Tuesday, November 21 with “Buy”. The firm has “Buy” rating given on Tuesday, November 22 by Lake Street. Zacks upgraded the stock to “Hold” rating in Tuesday, August 11 report. The stock has “Outperform” rating by Leerink Swann on Thursday, November 2. The stock has “Outperform” rating by Leerink Swann on Tuesday, November 21.

Analysts await AxoGen, Inc. (NASDAQ:AXGN) to report earnings on February, 28. They expect $-0.09 EPS, up 10.00% or $0.01 from last year’s $-0.1 per share. After $-0.06 actual EPS reported by AxoGen, Inc. for the previous quarter, Wall Street now forecasts 50.00% negative EPS growth.

More news for AxoGen, Inc. (NASDAQ:AXGN) were recently published by: Streetinsider.com, which released: “AxoGen, Inc. (AXGN) PT Raised to $27 at JMP Securities Following Analyst Day” on November 21, 2017. Streetinsider.com‘s article titled: “Jefferies Starts AxoGen, Inc. (AXGN) at Buy, Best Growth Story in Medtech” and published on November 30, 2017 is yet another important article.

More notable recent CVS Health Corporation (NYSE:CVS) news were published by: Reuters.com which released: “CVS Health to acquire Aetna for $69 billion in year’s largest acquisition” on December 03, 2017, also Thedenverchannel.com with their article: “UnitedHealth ventures deeper into patient care with $5B deal to buy DaVita …” published on December 06, 2017, Seekingalpha.com published: “CVS: Great For All – Apart From Shareholders” on December 08, 2017. More interesting news about CVS Health Corporation (NYSE:CVS) were released by: Seekingalpha.com and their article: “CVS Health – Attractive Long-Term Income Play” published on November 24, 2017 as well as Fool.com‘s news article titled: “Better Buy: CVS Health Corporation vs. Wal-Mart” with publication date: November 16, 2017.

Among 25 analysts covering CVS Health (NYSE:CVS), 17 have Buy rating, 0 Sell and 8 Hold. Therefore 68% are positive. CVS Health has $132 highest and $73 lowest target. $96.60’s average target is 35.88% above currents $71.09 stock price. CVS Health had 58 analyst reports since July 22, 2015 according to SRatingsIntel. On Tuesday, August 8 the stock rating was maintained by Oppenheimer with “Buy”. Goldman Sachs downgraded CVS Health Corporation (NYSE:CVS) on Thursday, December 17 to “Neutral” rating. The company was downgraded on Monday, February 6 by Atlantic Securities. As per Friday, April 28, the company rating was initiated by Tigress Financial. Robert W. Baird initiated CVS Health Corporation (NYSE:CVS) on Friday, January 22 with “Outperform” rating. Jefferies maintained CVS Health Corporation (NYSE:CVS) on Wednesday, October 18 with “Hold” rating. The stock has “Buy” rating by SunTrust on Friday, October 13. The rating was maintained by Jefferies on Friday, June 9 with “Hold”. The rating was maintained by Oppenheimer on Friday, August 28 with “Outperform”. Jefferies maintained CVS Health Corporation (NYSE:CVS) on Tuesday, November 7 with “Hold” rating.

Since June 12, 2017, it had 0 insider buys, and 1 insider sale for $18.44 million activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: